These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 9668196)

  • 21. Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin.
    Wong PC; Jiang X
    Thromb Haemost; 2010 Aug; 104(2):302-10. PubMed ID: 20589316
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Active site-directed thrombin inhibitors: alpha-hydroxyacyl-prolyl-arginals. New orally active stable analogs of D-Phe-Pro-Arg-H.
    Bajusz S; Barabás E; Fauszt I; Fehér A; Horváth G; Juhász A; Szabó AG; Széll E
    Bioorg Med Chem; 1995 Aug; 3(8):1079-89. PubMed ID: 7582981
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis, and anti-thrombotic evaluation of some novel fluorinated thrombin inhibitor derivatives.
    Chen H; Ren Y
    Arch Pharm (Weinheim); 2015 Jun; 348(6):408-20. PubMed ID: 25881141
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis and biological activity of novel rigid amidino-phenylalanine derivatives as inhibitors of thrombin.
    Mack H; Pfeiffer T; Hornberger W; Böhm HJ; Höffken HW
    J Enzyme Inhib; 1995; 9(1):73-86. PubMed ID: 8568568
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New tripeptidic thrombin inhibitors. Influence of P2 and P3 residues on activity and selectivity.
    De Nanteuil G; Gloanec P; Lila C; Portevin B; Boudon A; Rupin A; Verbeuren TJ
    Bioorg Med Chem; 1995 Aug; 3(8):1019-24. PubMed ID: 7582976
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and structure-activity relationships of potent thrombin inhibitors: piperazides of 3-amidinophenylalanine.
    Stürzebecher J; Prasa D; Hauptmann J; Vieweg H; Wikström P
    J Med Chem; 1997 Sep; 40(19):3091-9. PubMed ID: 9301673
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rational design and characterization of D-Phe-Pro-D-Arg-derived direct thrombin inhibitors.
    Figueiredo AC; Clement CC; Zakia S; Gingold J; Philipp M; Pereira PJ
    PLoS One; 2012; 7(3):e34354. PubMed ID: 22457833
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The design and synthesis of thrombin inhibitors: analogues of MD805 containing non-polar surrogates for arginine at the P1 position.
    Baettig U; Brown L; Brundish D; Dell C; Furzer A; Garman S; Janus D; Kane PD; Smith G; Walker CV; Cockcroft X; Ambler J; Mitchelson A; Talbot MD; Tweed M; Wills N
    Bioorg Med Chem Lett; 2000 Jul; 10(14):1563-6. PubMed ID: 10915051
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phenolic P2/P3 core motif as thrombin inhibitors--design, synthesis, and X-ray co-crystal structure.
    Hanessian S; Therrien E; van Otterlo WA; Bayrakdarian M; Nilsson I; Fjellström O; Xue Y
    Bioorg Med Chem Lett; 2006 Feb; 16(4):1032-6. PubMed ID: 16290930
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition by Argatroban, a specific thrombin inhibitor, of platelet activation by fibrin clot-associated thrombin.
    Lunven C; Gauffeny C; Lecoffre C; O'Brien DP; Roome NO; Berry CN
    Thromb Haemost; 1996 Jan; 75(1):154-60. PubMed ID: 8713795
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Functionality map analysis of the active site cleft of human thrombin.
    Grootenhuis PD; Karplus M
    J Comput Aided Mol Des; 1996 Feb; 10(1):1-10. PubMed ID: 8786410
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of glycyrrhizin as a thrombin inhibitor.
    Francischetti IM; Monteiro RQ; Guimarães JA
    Biochem Biophys Res Commun; 1997 Jun; 235(1):259-63. PubMed ID: 9196073
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 position.
    Tucker TJ; Brady SF; Lumma WC; Lewis SD; Gardell SJ; Naylor-Olsen AM; Yan Y; Sisko JT; Stauffer KJ; Lucas BJ; Lynch JJ; Cook JJ; Stranieri MT; Holahan MA; Lyle EA; Baskin EP; Chen IW; Dancheck KB; Krueger JA; Cooper CM; Vacca JP
    J Med Chem; 1998 Aug; 41(17):3210-9. PubMed ID: 9703466
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structure-activity and crystallographic analysis of a new class of non-amide-based thrombin inhibitor.
    Lu T; Soll RM; Illig CR; Bone R; Murphy L; Spurlino J; Salemme FR; Tomczuk BE
    Bioorg Med Chem Lett; 2000 Jan; 10(1):79-82. PubMed ID: 10636249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 1-Aminoisoquinoline as benzamidine isoster in the design and synthesis of orally active thrombin inhibitors.
    Rewinkel JB; Lucas H; van Galen PJ; Noach AB; van Dinther TG; Rood AM; Jenneboer AJ; van Boeckel CA
    Bioorg Med Chem Lett; 1999 Mar; 9(5):685-90. PubMed ID: 10201829
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolism-directed optimization of 3-aminopyrazinone acetamide thrombin inhibitors. Development of an orally bioavailable series containing P1 and P3 pyridines.
    Burgey CS; Robinson KA; Lyle TA; Sanderson PE; Lewis SD; Lucas BJ; Krueger JA; Singh R; Miller-Stein C; White RB; Wong B; Lyle EA; Williams PD; Coburn CA; Dorsey BD; Barrow JC; Stranieri MT; Holahan MA; Sitko GR; Cook JJ; McMasters DR; McDonough CM; Sanders WM; Wallace AA; Clayton FC; Bohn D; Leonard YM; Detwiler TJ; Lynch JJ; Yan Y; Chen Z; Kuo L; Gardell SJ; Shafer JA; Vacca JP
    J Med Chem; 2003 Feb; 46(4):461-73. PubMed ID: 12570369
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bifunctional peptide boronate inhibitors of thrombin: crystallographic analysis of inhibition enhanced by linkage to an exosite 1 binding peptide.
    Skordalakes E; Elgendy S; Goodwin CA; Green D; Scully MF; Kakkar VV; Freyssinet JM; Dodson G; Deadman JJ
    Biochemistry; 1998 Oct; 37(41):14420-7. PubMed ID: 9772168
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thrombin inhibitors with novel P1 binding pocket functionality: free energy of binding analysis.
    Mlinsek G; Oblak M; Hodoscek M; Solmajer T
    J Mol Model; 2007 Jan; 13(1):247-54. PubMed ID: 17013633
    [TBL] [Abstract][Full Text] [Related]  

  • 39. P3 optimization of functional potency, in vivo efficacy and oral bioavailability in 3-aminopyrazinone thrombin inhibitors bearing non-charged groups at the P1 position.
    Isaacs RC; Newton CL; Cutrona KJ; Mercer SP; Dorsey BD; McDonough CM; Cook JJ; Krueger JA; Lewis SD; Lucas BJ; Lyle EA; Lynch JJ; Miller-Stein C; Michener MT; Wallace AA; White RB; Wong BK
    Bioorg Med Chem Lett; 2011 Mar; 21(5):1532-5. PubMed ID: 21295466
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structure-based design and synthesis of novel thrombin inhibitors based on phosphinic peptide mimetics.
    Li M; Lin Z; Johnson ME
    Bioorg Med Chem Lett; 1999 Jul; 9(14):1957-62. PubMed ID: 10450962
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.